Trial Profile
Phase I clinical trial of KD 019 in patients with previously treated, Src- and HER2-positive, metastatic breast cancer, with and without metastases to the brain.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2014
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kadmon Corporation
- 09 Apr 2014 New trial record